Review
Multidisciplinary Sciences
Andre Eduardo de Almeida Franzoi, Fernanda Subtil de Moraes Machado, Washigton Luiz Gomes de Medeiros Junior, Isabelle Pastor Bandeira, Wesley Nogueira Brandao, Marcus Vinicius Magno Goncalves
Summary: miRNAs play crucial roles in MS by regulating gene expression in various cells. NTZ treatment modifies gene expression and miRNA levels in B cells, indicating a potential for specific miRNAs to serve as markers of therapeutic response in MS patients. Understanding the complex interaction between miRNAs, gene expression in B cells, and therapeutic response is important for MS treatment.
Article
Clinical Neurology
Clara G. Chisari, Simona Toscano, Sebastiano Arena, Chiara Finocchiaro, Arturo Montineri, Francesco Patti
Summary: This case series presents the clinical outcomes of MS patients receiving NTZ during active COVID-19 infection. Most patients were asymptomatic, with one experiencing a slightly worse COVID-19 course. None required O2 therapy or intensive care, and no neurological complications were observed.
Article
Immunology
Javier Riancho, Sonia Setien, Jose Ramon Sanchez de la Torre, Marta Torres-Barquin, Mercedes Misiego, Jose Luis Perez, Tamara Castillo-Trivino, Cristina Menendez-Garcia, Manuel Delgado-Alvarado
Summary: Observational study on the long-term effectiveness of natalizumab with extended interval dosing (EID) in multiple sclerosis patients treated for over 7 years showed that EID preserved treatment efficacy and prevented disability worsening during follow-up. Patients treated with natalizumab for the first time showed slightly better response to EID therapy compared to those previously treated with other immunosuppressive drugs.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Jae-Won Hyun, Ho Jin Kim
Summary: This study evaluated the efficacy and safety of natalizumab in Korean patients with active MS, showing high efficacy in reducing annual relapse rate and improving or stabilizing disability in the majority of patients. NEDA-3 was achieved in 92% and 82% of patients at 1 and 2 years after initiating natalizumab treatment, respectively. No serious adverse events leading to discontinuation of natalizumab were observed.
FRONTIERS IN NEUROLOGY
(2021)
Article
Public, Environmental & Occupational Health
G. Piatti, M. Sartini, C. Cusato, A. M. Schito
Summary: This study retrospectively analyzed the incidence of Candida auris infections in the intensive care units of an Italian hospital and compared the relationship between cutaneous and intestinal colonization. The results showed that the proportion of skin and intestinal colonization by Candida auris was similar, and intestinal colonization was associated with an increased risk of urinary tract infections.
JOURNAL OF HOSPITAL INFECTION
(2022)
Review
Clinical Neurology
Sarah A. Morrow, Fraser Clift, Virginia Devonshire, Emmanuelle Lapointe, Raphael Schneider, Mark Stefanelli, Reza Vosoughi
Summary: A group of neurologists from Canada convened in September 2021 to update the 2015 Canadian practice recommendations for the use of natalizumab in patients with multiple sclerosis (MS). The updated recommendations focus on long-term efficacy and safety data, patient selection based on JCV index criteria, risk management strategies for progressive leukoencephalopathy (PML), and options for switching to alternative disease-modifying therapies.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Kevin Bigaut, Laurent Kremer, Thibaut Fabacher, Guido Ahle, Mathilde Goudot, Marie Fleury, Claude Gaultier, Sylvie Courtois, Nicolas Collongues, Jerome de Seze
Summary: This study compared the effectiveness of ocrelizumab and fingolimod after natalizumab cessation. The results showed that ocrelizumab had a significantly lower relapse rate at 1 year compared to fingolimod.
JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Chao Zhu, Zhen Zhou, Izanne Roos, Daniel Merlo, Tomas Kalincik, Serkan Ozakbas, Olga Skibina, Jens Kuhle, Suzanne Hodgkinson, Cavit Boz, Raed Alroughani, Jeannette Lechner-Scott, Michael Barnett, Guillermo Izquierdo, Alexandre Prat, Dana Horakova, Eva Kubala Havrdova, Richard Macdonell, Francesco Patti, Samia Joseph Khoury, Mark Slee, Rana Karabudak, Marco Onofrj, Vincent Van Pesch, Julie Prevost, Mastura Monif, Vilija Jokubaitis, Anneke van der Walt, Helmut Butzkueven
Summary: Ocrelizumab and natalizumab are more effective than cladribine in reducing relapses in patients with relapsing-remitting multiple sclerosis switching from fingolimod. Additional observation time is needed to determine if the statistical difference in annualized relapse rate (ARR) results in long-term disability differences.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2022)
Article
Immunology
Undine Proschmann, Rocco Haase, Hernan Inojosa, Katja Akgun, Tjalf Ziemssen
Summary: This study observed women treated with natalizumab during pregnancy and lactation, finding that most patients did not experience disease activity during gestation and postpartum. Natalizumab concentration in breastmilk was low but detectable sNfL levels were present in most samples.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Clinical Neurology
Alyssa A. Toorop, Zoe L. E. van Kempen, Maurice Steenhuis, Jessica Nielsen, L. G. F. Sinnige, Gert van Dijk, Christiaan M. Roosendaal, Edo P. J. Arnoldus, Elske Hoitsma, Birgit Lissenberg-Witte, Brigit A. de Jong, Bob W. van Oosten, Eva M. M. Strijbis, Bernard M. J. Uitdehaag, Theo Rispens, Joep Killestein
Summary: The study evaluated the change in natalizumab trough drug levels when switching from intravenous to subcutaneous administration. It was found that the drug levels were on average 55% lower with subcutaneous administration, leading to very low levels in some patients. Monitoring of trough drug levels is advised when switching to subcutaneous administration in patients with low intravenous drug levels, higher body mass index, or extended treatment intervals.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Virology
Simone Agostini, Roberta Mancuso, Andrea Saul Costa, Domenico Caputo, Mario Clerici
Summary: The detection of miR-J1-5p in urine of MS patients treated with Natalizumab could potentially serve as a biomarker to monitor JCPyV infection and better identify the risk of developing PML. The study found miR-J1-5p in the urine of 28% of patients, even in some cases where JCPyV DNA was not detected in urine or blood. This suggests that miR-J1-5p measurement could be valuable in assessing PML risk in Natalizumab-treated MS patients.
Article
Medicine, General & Internal
Ranjani Ganapathy Subramanian, Dana Horakova, Manuela Vaneckova, Balazs Lorincz, Jan Krasensky, Eva Kubala Havrdova, Tomas Uher
Summary: The study found that natalizumab treatment can reduce inflammatory markers in the cerebrospinal fluid of multiple sclerosis patients, decrease the levels of white blood cells and proteins, as well as the number of oligoclonal bands in the cerebrospinal fluid. Additionally, the baseline IgM index was found to predict brain volume loss during natalizumab treatment.
Article
Medical Laboratory Technology
Lesley J. Page, Jacqueline Lagunas-Acosta, Raphaela Heussen, Edward T. Castellana, Bradley T. Messmer
Summary: A novel assay was developed to quantify unexchanged and exchanged natalizumab variants in clinical samples. This assay will enable investigations into the clinical significance of the relationship between PK/PD and the monovalent-to-bivalent ratio, as it relates to the efficacy of the drug and risk of PML.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Clinical Neurology
Alyssa A. Toorop, Theo Rispens, Eva M. M. Strijbis, Bob W. van Oosten, Brigit A. de Jong, Bernard M. J. Uitdehaag, Joep Killestein, Zoe L. E. van Kempen
Summary: In pregnant women with very active multiple sclerosis, Natalizumab concentrations gradually decrease during pregnancy, especially in patients with low initial trough concentrations or extended interval dosing. After delivery, Natalizumab concentrations return to pre-pregnancy levels, and patients remain clinically and radiologically stable. MS neurologists should be aware of these changes in drug concentrations during pregnancy.
MULTIPLE SCLEROSIS JOURNAL
(2022)
Article
Clinical Neurology
Eva M. Strijbis, Eline Coerver, Jop Mostert, Zoe L. E. van Kempen, Joep Killestein, Jacynthe Comtois, Pavle Repovic, James D. Bowen, Gary Cutter, Marcus Koch
Summary: This study investigates the association between age and inflammatory disease activity in relapsing-remitting multiple sclerosis (RRMS) using patient-level data from randomized controlled trials (RCTs) of natalizumab treatment. The results show that older age is associated with lower prevalence and degree of focal inflammatory disease activity in treated and untreated RRMS patients. These findings provide important insights for the design of RCTs and the decision-making process of immunomodulatory treatment in RRMS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)